Middle East Respiratory Syndrome (MERS) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Middle East Respiratory Syndrome (MERS) – Pipeline Review, H2 2016’, provides an overview of the Middle East Respiratory Syndrome (MERS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS)

The report reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Middle East Respiratory Syndrome (MERS) therapeutics and enlists all their major and minor projects

The report assesses Middle East Respiratory Syndrome (MERS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Middle East Respiratory Syndrome (MERS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Atriva Therapeutics GmbH

Autoimmune Technologies LLC

Humabs BioMed SA

Inovio Pharmaceuticals Inc

Nanotherapeutics Inc

Novavax Inc

Phelix Therapeutics LLC

Planet Biotechnology Inc

Regeneron Pharmaceuticals Inc

Romark Laboratories LC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Middle East Respiratory Syndrome (MERS) Overview 7

Therapeutics Development 8

Pipeline Products for Middle East Respiratory Syndrome (MERS) - Overview 8

Pipeline Products for Middle East Respiratory Syndrome (MERS) - Comparative Analysis 9

Middle East Respiratory Syndrome (MERS) - Therapeutics under Development by Companies 10

Middle East Respiratory Syndrome (MERS) - Therapeutics under Investigation by Universities/Institutes 11

Middle East Respiratory Syndrome (MERS) - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Middle East Respiratory Syndrome (MERS) - Products under Development by Companies 14

Middle East Respiratory Syndrome (MERS) - Products under Investigation by Universities/Institutes 15

Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development 16

Atriva Therapeutics GmbH 16

Autoimmune Technologies LLC 17

Humabs BioMed SA 18

Inovio Pharmaceuticals Inc 19

Nanotherapeutics Inc 20

Novavax Inc 21

Phelix Therapeutics LLC 22

Planet Biotechnology Inc 23

Regeneron Pharmaceuticals Inc 24

Romark Laboratories LC 25

Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

3B-11 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

ATR-006 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

BNSP-333S1 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

CSW-1 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

FBR-001 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

INO-4500 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

LCA-60 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Middle East respiratory syndrome coronavirus vaccine - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Middle East respiratory syndrome coronavirus vaccine - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Middle East respiratory syndrome vaccine - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Middle East respiratory syndrome vaccine - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

nitazoxanide - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

REGN-3048 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

REGN-3051 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

SAB-301 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Middle East Respiratory Syndrome (MERS) - Product Development Milestones 55

Featured News & Press Releases 55

Dec 06, 2016: Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute 55

Aug 24, 2016: SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment 55

Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment 56

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

List of Tables

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2016 8

Number of Products under Development for Middle East Respiratory Syndrome (MERS) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Middle East Respiratory Syndrome (MERS) – Pipeline by Atriva Therapeutics GmbH, H2 2016 16

Middle East Respiratory Syndrome (MERS) – Pipeline by Autoimmune Technologies LLC, H2 2016 17

Middle East Respiratory Syndrome (MERS) – Pipeline by Humabs BioMed SA, H2 2016 18

Middle East Respiratory Syndrome (MERS) – Pipeline by Inovio Pharmaceuticals Inc, H2 2016 19

Middle East Respiratory Syndrome (MERS) – Pipeline by Nanotherapeutics Inc, H2 2016 20

Middle East Respiratory Syndrome (MERS) – Pipeline by Novavax Inc, H2 2016 21

Middle East Respiratory Syndrome (MERS) – Pipeline by Phelix Therapeutics LLC, H2 2016 22

Middle East Respiratory Syndrome (MERS) – Pipeline by Planet Biotechnology Inc, H2 2016 23

Middle East Respiratory Syndrome (MERS) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 24

Middle East Respiratory Syndrome (MERS) – Pipeline by Romark Laboratories LC, H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Assessment by Combination Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2016 8

Number of Products under Development for Middle East Respiratory Syndrome (MERS) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Targets, H2 2016 28

Number of Products by Stage and Targets, H2 2016 28

Number of Products by Mechanism of Actions, H2 2016 30

Number of Products by Stage and Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports